Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Feb 24:9:13.
doi: 10.1186/1476-072X-9-13.

Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages

Affiliations

Selection for resistance to oseltamivir in seasonal and pandemic H1N1 influenza and widespread co-circulation of the lineages

Daniel A Janies et al. Int J Health Geogr. .

Abstract

Background: In Spring 2009, a novel reassortant strain of H1N1 influenza A emerged as a lineage distinct from seasonal H1N1. On June 11, the World Heath Organization declared a pandemic - the first since 1968. There are currently two main branches of H1N1 circulating in humans, a seasonal branch and a pandemic branch. The primary treatment method for pandemic and seasonal H1N1 is the antiviral drug Tamiflu (oseltamivir). Although many seasonal H1N1 strains around the world are resistant to oseltamivir, initially, pandemic H1N1 strains have been susceptible to oseltamivir. As of February 3, 2010, there have been reports of resistance to oseltamivir in 225 cases of H1N1 pandemic influenza. The evolution of resistance to oseltamivir in pandemic H1N1 could be due to point mutations in the neuraminidase or a reassortment event between seasonal H1N1 and pandemic H1N1 viruses that provide a neuraminidase carrying an oseltamivir-resistant genotype to pandemic H1N1.

Results: Using phylogenetic analysis of neuraminidase sequences, we show that both seasonal and pandemic lineages of H1N1 are evolving to direct selective pressure for resistance to oseltamivir. Moreover, seasonal lineages of H1N1 that are resistant to oseltamivir co-circulate with pandemic H1N1 throughout the globe. By combining phylogenetic and geographic data we have thus far identified 53 areas of co-circulation where reassortment can occur. At our website POINTMAP, http://pointmap.osu.edu we make available a visualization and an application for updating these results as more data are released.

Conclusions: As oseltamivir is a keystone of preparedness and treatment for pandemic H1N1, the potential for resistance to oseltamivir is an ongoing concern. Reassortment and, more likely, point mutation have the potential to create a strain of pandemic H1N1 against which we have a reduced number of treatment options.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Screen shot of an interactive visualization of populations of oseltamivir-resistant seasonal H1N1 influenza and pandemic H1N1 influenza in co-circulation across the globe. The visualization is available via a web browser on our website POINTMAP http://pointmap.osu.edu or in additional file 8 associated with the paper.

Similar articles

Cited by

References

    1. WHO. Pandemic (H1N1) 2009 - update 58. 2009. http://www.who.int/csr/don/2009_07_06/en/index.html
    1. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis. 2009. - PMC - PubMed
    1. Hurt AC, Ernesta J, Denga Y, Iannelloa P, Besselaarc T. Emergence and spread of oseltamivir-resistant A (H1N1) influenza viruses in Oceania, South East Asia and South Africa. Antiviral Research. 2009;83:90–93. doi: 10.1016/j.antiviral.2009.03.003. - DOI - PubMed
    1. WHO. "Pandemic (H1N1) 2009 - update 83". http://www.who.int/csr/disease/swineflu/laboratory15_01_2010/en/index.html
    1. CDC. Oseltamivir-Resistant Novel Influenza A (H1N1) Virus Infection in Two Immunosuppressed Patients - Seattle, Washington, 2009. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm58d0814a1.htm - PubMed

Publication types

MeSH terms